These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 31884422)
1. Genome-wide global identification of NRF2 binding sites in A549 non-small cell lung cancer cells by ChIP-Seq reveals NRF2 regulation of genes involved in focal adhesion pathways. Namani A; Liu K; Wang S; Zhou X; Liao Y; Wang H; Wang XJ; Tang X Aging (Albany NY); 2019 Dec; 11(24):12600-12623. PubMed ID: 31884422 [TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257 [TBL] [Abstract][Full Text] [Related]
3. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer. Namani A; Matiur Rahaman M; Chen M; Tang X BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329 [TBL] [Abstract][Full Text] [Related]
4. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma. Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269 [TBL] [Abstract][Full Text] [Related]
5. NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer. Namani A; Cui QQ; Wu Y; Wang H; Wang XJ; Tang X Oncotarget; 2017 Sep; 8(41):69847-69862. PubMed ID: 29050246 [TBL] [Abstract][Full Text] [Related]
6. Nrf2 regulates cell motility through RhoA-ROCK1 signalling in non-small-cell lung cancer cells. Ko E; Kim D; Min DW; Kwon SH; Lee JY Sci Rep; 2021 Jan; 11(1):1247. PubMed ID: 33441941 [TBL] [Abstract][Full Text] [Related]
7. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein. Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391 [TBL] [Abstract][Full Text] [Related]
8. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. Mahaffey CM; Mahaffey NC; Holland W; Zhang H; Gandara DR; Mack PC; Forman HJ J Thorac Oncol; 2012 Jan; 7(1):34-9. PubMed ID: 22089114 [TBL] [Abstract][Full Text] [Related]
9. Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer. Zeng Z; Wang ZY; Li YK; Ye DM; Zeng J; Hu JL; Chen PF; Xiao J; Zou J; Li ZH Life Sci; 2020 Aug; 254():117325. PubMed ID: 31954159 [TBL] [Abstract][Full Text] [Related]
10. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Malhotra D; Portales-Casamar E; Singh A; Srivastava S; Arenillas D; Happel C; Shyr C; Wakabayashi N; Kensler TW; Wasserman WW; Biswal S Nucleic Acids Res; 2010 Sep; 38(17):5718-34. PubMed ID: 20460467 [TBL] [Abstract][Full Text] [Related]
11. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771 [TBL] [Abstract][Full Text] [Related]
12. Emerging roles of Nrf2 signal in non-small cell lung cancer. Tian Y; Liu Q; He X; Yuan X; Chen Y; Chu Q; Wu K J Hematol Oncol; 2016 Feb; 9():14. PubMed ID: 26922479 [TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Mahaffey CM; Zhang H; Rinna A; Holland W; Mack PC; Forman HJ Free Radic Biol Med; 2009 Jun; 46(12):1650-7. PubMed ID: 19345732 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic modifications but not genetic polymorphisms regulate KEAP1 expression in colorectal cancer. Gao L; Yuan F; Che G; Xiao X; Nie X; Wang Y; Jia J; Kong AN; Zhang L J Cell Biochem; 2019 Aug; 120(8):12311-12320. PubMed ID: 30825237 [TBL] [Abstract][Full Text] [Related]
15. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer. Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007 [TBL] [Abstract][Full Text] [Related]
16. Withaferin A induces heme oxygenase (HO-1) expression in endothelial cells via activation of the Keap1/Nrf2 pathway. Heyninck K; Sabbe L; Chirumamilla CS; Szarc Vel Szic K; Vander Veken P; Lemmens KJA; Lahtela-Kakkonen M; Naulaerts S; Op de Beeck K; Laukens K; Van Camp G; Weseler AR; Bast A; Haenen GRMM; Haegeman G; Vanden Berghe W Biochem Pharmacol; 2016 Jun; 109():48-61. PubMed ID: 27045103 [TBL] [Abstract][Full Text] [Related]
17. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680 [TBL] [Abstract][Full Text] [Related]
18. NRF2-Driven Tian Y; Liu Q; Yu S; Chu Q; Chen Y; Wu K; Wang L Mol Cancer Res; 2020 Oct; 18(10):1465-1476. PubMed ID: 32571982 [TBL] [Abstract][Full Text] [Related]
19. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer. Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567 [TBL] [Abstract][Full Text] [Related]
20. Genome-wide identification and analysis of Nrf2 binding sites - Antioxidant response elements in zebrafish. Raghunath A; Nagarajan R; Sundarraj K; Panneerselvam L; Perumal E Toxicol Appl Pharmacol; 2018 Dec; 360():236-248. PubMed ID: 30243843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]